Bard patent upheld in $185m Gore row:
This article was originally published in Clinica
C R Bard has been awarded $185m in past damages after a US court ruled that W L Gore & Associates had infringed one of the former's patents. The district court of Arizona upheld the validity of Bard's patent '135 and found that certain components of Gore's ePTFE vascular grafts and stent-grafts range had wilfully infringed the patent. The same court is also assessing Gore's claims that the patent is unenforceable due to inequitable conduct. Bard said that it expects Gore to file post-trial motions to the Court of Appeals, after the jury's decision.
You may also be interested in...
Pain relief product sales grew 27% and upper respiratory sales 35% for the week ended 7 March as consumers respond to COVID-19, according to Nielsen data noted in a Jefferies report on consumer health purchasing trends. Private label market share is up slightly, while OTC purchases continue primarily in conventional stores.
Managing partner Corey Goodman said venBio didn’t have trouble closing its fund, because the venture capital firm prepared its investors for an economic downturn months ago.
The US FDA has proposed moving two categories of hepatitis C diagnostics to class II from class III because they pose relatively low risk.